Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review ; volume:21 ; number:1 ; day:17 ; month:4 ; year:2021 ; pages:1-14 ; date:12.2021
BMC cancer ; 21, Heft 1 (17.4.2021), 1-14, 12.2021
- Urheber
-
Spagnolo, Francesco
Boutros, Andrea
Cecchi, Federica
Croce, Elena
Tanda, Enrica Teresa
Queirolo, Paola
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08165-0
- URN
-
urn:nbn:de:101:1-2021060511260009831853
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Spagnolo, Francesco
- Boutros, Andrea
- Cecchi, Federica
- Croce, Elena
- Tanda, Enrica Teresa
- Queirolo, Paola
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy